Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients
Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
In this first in human study the aim is to assess the safety, pharmacokinetics and
pharmacodynamics of 2B3-201 in a randomized, first in human, double-blind, placebo- and
active comparator- controlled 3-way crossover study in 18 healthy male subjects (part 1).
Furthermore, the findings obtained from part 1 will be extended and confirmed in a subsequent
parallel open label study in 18 healthy male and 12 MS patients and an open label study with
methylprednisolone as comparator in 12 female volunteers (part 2).